糖尿病心肌病治疗的进展,一个系统的审查
Yiyi Shou1, Xingyu Li1, Quan Fang1
1Department of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Pharmacology research & perspectives
|February 26, 2024
概括
糖尿病心肌病 (DCM) 是糖尿病人没有其他心脏风险的心脏疾病. 目前的治疗方法有限,这凸显了对抗高心力衰竭率的新疗法的需要.
科学领域:
- 心血管医学 心血管医学
- 内分泌学 在内分泌学.
- 病理学 病理学 病理学
背景情况:
- 糖尿病心肌病 (DCM) 是糖尿病中心肌功能障碍,独立于其他心血管风险.
- 病理学特征包括缩,纤维化,心室功能受损和亡.
- DCM可能导致心力衰竭,心律失常和心脏突然死亡.
研究的目的:
- 为DCM提供当前治疗方式的概述.
- 讨论DCM的新技术和研究方向.
- 支持研究人员调查这种复杂的糖尿病并发症.
主要方法:
- 审查关于DCM的现有文献.
- 对当前治疗方法的分析.
- 探索新兴的研究和技术.
主要成果:
- 目前,DCM在临床实践中没有特定的向疗法.
- 在DCM患者中,心力衰竭发病率和死亡率仍然很高.
- 目前正在进行的研究旨在确定DCM的有效治疗方法.
结论:
- 迫切需要针对糖尿病心肌病的有效,有针对性的治疗方法.
- 对新型治疗方式的进一步研究至关重要.
- 了解DCM的病理生理学是开发更好的干预措施的关键.
相关概念视频
01:15Diabetes: Management and Pharmacotherapy
283
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
283
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431